Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial
Neoadjuvant camrelizumab plus trastuzumab and chemotherapy demonstrated favorable response and tolerable safety in HER2-positive G/GEJ adenocarcinoma.
Authors
- Suxia Luo (ORCID: https://orcid.org/0000-0002-5267-8417)
- Qingxin Xia (ORCID: https://orcid.org/0000-0003-0216-9179)
- Zhandong Zhang (ORCID: https://orcid.org/0000-0002-0222-170X)
- Jinbang Wang (ORCID: https://orcid.org/0000-0002-8827-9354)
- Chuang Shang
- Ning Li (ORCID: https://orcid.org/0000-0002-6312-5260)
- Bin Zhang (ORCID: https://orcid.org/0000-0001-7940-0661)
- Jian Zhang (ORCID: https://orcid.org/0000-0002-6558-791X)
- He Zhang (ORCID: https://orcid.org/0000-0001-9198-6503)
- Jing Li (ORCID: https://orcid.org/0009-0008-1301-2533)
- Zhi Li (ORCID: https://orcid.org/0009-0008-9163-6907)
- Wei Chen (ORCID: https://orcid.org/0000-0002-8159-5514)
- Yongchao Zhang (ORCID: https://orcid.org/0000-0001-5634-6156)
- Yijie Ma
- Qiang Fu (ORCID: https://orcid.org/0000-0001-8275-8883)
- Xiangbin Wan
- Liangyu Bie
Institutions
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- Gastric Cancer
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1007/s10120-025-01606-w
- Citations
- 3
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Innovative Research Group Project of the National Natural Science Foundation of China
- National Natural Science Foundation of China
- Henan Provincial Science and Technology Research Project